Payment overview · 2025
General Payments
$754.78
42 reported records · 17 companies
Healthcare provider profile · identity verified
Todd Mitchell Wien, MD
Allopathic & Osteopathic Physicians|Family Medicine · PLANO, TX · NPI 1265440275
Verified facts
What the public records show
CMS Open Payments records show Todd Mitchell Wien, MD received $754.78 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.80 | 25.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.29 | 20.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.80 | 11.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.05 | 7.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.71 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.65 | 3.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.36 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.64 | 3.7% | 2 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $24.75 | 3.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.28 | 2.7% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.07 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.35 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.05 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.57 | 2.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $15.18 | 2.0% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $14.72 | 1.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $13.51 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $754.78 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.33 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $99.49 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.47 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.98 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.54 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.54 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.80 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.05 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.65 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $28.65 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.65 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 76 |
| Alprazolam | Alprazolam | 270 | 66 |
| Metformin Hcl Er | Metformin Hcl | 247 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 75 |
| Simvastatin | Simvastatin | 219 | 58 |
| Lisinopril | Lisinopril | 218 | 61 |
| Meloxicam | Meloxicam | 215 | 67 |
| Losartan Potassium | Losartan Potassium | 204 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 42 |
| Montelukast Sodium | Montelukast Sodium | 159 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 159 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 47 |
| Omeprazole | Omeprazole | 150 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 147 | 32 |
| Ozempic | Semaglutide | 139 | 32 |
| Gabapentin | Gabapentin | 138 | 34 |
| Trazodone Hcl | Trazodone Hcl | 131 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 39 |
| Tramadol Hcl | Tramadol Hcl | 122 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 30 |
| Carvedilol | Carvedilol | 107 | 31 |
| Allopurinol | Allopurinol | 105 | 27 |
| Lovastatin | Lovastatin | 105 | 27 |
| Furosemide | Furosemide | 104 | 27 |
| Glipizide Er | Glipizide | 101 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 23 |
| Sertraline Hcl | Sertraline Hcl | 90 | 21 |
| Temazepam | Temazepam | 90 | 25 |
| Finasteride | Finasteride | 80 | 20 |
| Azithromycin | Azithromycin | 79 | 72 |
| Clonazepam | Clonazepam | 79 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 71 | 12 |
| Anastrozole | Anastrozole | 70 | 21 |
| Metformin Hcl | Metformin Hcl | 69 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 21 |
| Trulicity | Dulaglutide | 68 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 65 | 17 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Prednisone | Prednisone | 62 | 36 |
| Buspirone Hcl | Buspirone Hcl | 61 | 19 |
| Lorazepam | Lorazepam | 61 | 11 |
| Synthroid | Levothyroxine Sodium | 61 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 21 |
| Bupropion Xl | Bupropion Hcl | 58 | 14 |
| Potassium Chloride | Potassium Chloride | 58 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 14 |
| Farxiga | Dapagliflozin Propanediol | 57 | 16 |
| Ezetimibe | Ezetimibe | 56 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 23 |
| Jardiance | Empagliflozin | 55 | 11 |
| Diazepam | Diazepam | 53 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 29 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Spironolactone | Spironolactone | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Methylprednisolone | Methylprednisolone | 42 | 33 |
| Nystatin | Nystatin | 42 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 17 |
| Ramipril | Ramipril | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 13 |
| Famotidine | Famotidine | 35 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 13 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Estradiol | Estradiol | 27 | 13 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Prozac | Fluoxetine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $754.78 · 42 records | ABBVIE INC. | AREXVY, BEXSERO, BREZTRI, CRYSVITA, Dexcom G6 Transmitter, ELIQUIS, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fluad, Flucelvax, Heplisav-B, JARDIANCE, Leqembi, NURTEC ODT, Ozempic, QULIPTA, REXULTI, SHINGRIX, UBRELVY, VRAYLAR, VYNDAQEL, Veozah, WatchPATONE, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error